Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Ji Wang; Chenyang Ye; Hanchu Xiong; Yong Shen; Yi Lu; Jichun Zhou; Linbo Wang

doi:10.18632/oncotarget.12537

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Ji Wang _, Chenyang Ye, Hanchu Xiong, Yong Shen, Yi Lu, Jichun Zhou and Linbo Wang

PDF | HTML | How to cite

Oncotarget. 2017; 8:5508-5522. https://doi.org/10.18632/oncotarget.12537

Metrics: PDF 3157 views | HTML 5351 views | ?

Abstract

Ji Wang1,2,*, Chenyang Ye3,*, Hanchu Xiong1,2, Yong Shen4, Yi Lu1,2, Jichun Zhou1,2 and Linbo Wang1,2

1 Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China

2 Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, China

3 Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education), Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

4 Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

* These authors have contributed equally to this work

Correspondence to:

Jichun Zhou, email:

Linbo Wang, email:

Keywords: breast cancer; long non-coding RNA; mechanism; biomarker; treatment target

Received: July 10, 2016 Accepted: October 03, 2016 Published: October 08, 2016

Abstract

Long non-coding RNAs (lncRNAs), which occupy nearly 98% of genome, have crucial roles in cancer development, including breast cancer. Breast cancer is a disease with high incidence. Despite of recent progress in understanding the molecular mechanisms and combined therapy strategies, the functions and mechanisms of lncRNAs in breast cancer remains unclear. This review presents the currently basic knowledge and research approaches of lncRNAs. We also highlight the latest advances of seven classic lncRNAs and three novel lncRNAs in breast cancer, elucidating their mechanisms and possible therapeutic targets. Additionally, association between lncRNA and specific molecular subtype of breast cancer is reported. Lastly, we briefly delineate the potential roles of lncRNAs in clinical applications as biomarkers and treatment targets.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12537

Publication Alerts

Reviews:

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Abstract